The timing of cyclic cytotoxic chemotherapy can worsen neutropenia and neutrophilia.

British Journal of Clinical Pharmacology
Michael C MackeyMorgan Craig

Abstract

Despite recent advances in immunotherapies, cytotoxic chemotherapy continues to be a first-line treatment option for the majority of cancers. Unfortunately, a common side effect in patients undergoing chemotherapy treatment is neutropenia. To mitigate the risk of neutropenia and febrile neutropenia, prophylactic treatment with granulocyte-colony stimulating factor (G-CSF) is administered. Extensive pharmacokinetic/pharmacodynamic modelling of myelosuppression during chemotherapy has suggested avenues for therapy optimization to mitigate this neutropenia. However, the issue of resonance, whereby neutrophil oscillations are induced by the periodic administration of cytotoxic chemotherapy and the coadministration of G-CSF, potentially aggravating a patient's neutropenic/neutrophilic status, is not well-characterized in the clinical literature. Here, through analysis of neutrophil data from young acute lymphoblastic leukaemia patients, we find that resonance is occurring during cyclic chemotherapy treatment in 26% of these patients. Motivated by these data and our previous modelling studies on adult lymphoma patients, we examined resonance during treatment with or without G-CSF. Using our quantitative systems pharmacology model of ...Continue Reading

References

Jan 1, 1992·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Z AgurB Schechter
May 1, 1986·American Journal of Hematology·D B LensinkW P Hammond
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jean Marie LeClercStephen E Sallan
Aug 2, 2003·Investigational New Drugs·Lena E Friberg, Mats O Karlsson
Dec 23, 2004·Journal of Mathematical Biology·M ScholzM Loeffler
Jun 24, 2008·Pediatric Hematology and Oncology·Sameer BakhshiL S Arya
Dec 25, 2008·Journal of Pharmacokinetics and Pharmacodynamics·C MeilleG Freyer
Sep 1, 2004·Journal of the National Comprehensive Cancer Network : JNCCN·Alison G FreifeldUNKNOWN National Comprehensive Cancer Network
May 19, 2011·Cancer Chemotherapy and Pharmacology·Carlos Pérez-RuixoJuan José Pérez-Ruixo
Jan 29, 2013·Hematology/oncology Clinics of North America·Marshall S HorwitzTimothy Tidwell
Sep 13, 2014·Bulletin of Mathematical Biology·David C Dale, Michael C Mackey
Aug 13, 2015·Anti-cancer Drugs·Yasunori HashiguchiToshiyuki Sumi
Jan 15, 2016·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J M MichotO Lambotte
Apr 19, 2017·CPT: Pharmacometrics & Systems Pharmacology·M Craig
May 24, 2017·The Pharmacogenomics Journal·S J GlisovicM Krajinovic
Mar 7, 2018·Current Oncology·G JutrasM Florescu

❮ Previous
Next ❯

Citations

Aug 2, 2020·Bulletin of Mathematical Biology·Tyler CassidyMichael C Mackey

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.